Drug-induced liver steatosis and phospholipidosis: Cell-based assays for early screening of drug candidates

Current Drug Metabolism

Volumn 13, Issue 8, 2012, Pages 1160-1173

  Teresa Donato, M ^a,b,c   Gómez Lechón, M José ^a,b  

^a INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Cell based assay; Drug; Hepatotoxicity; Phospholipidosis; Steatosis

Indexed keywords

4 PENTENOIC ACID; AMINEPTINE; AMIODARONE; ANTIANGINA PECTORIS AGENT; ANTIDEPRESSANT AGENT; ANTIMALARIAL AGENT; CHLOROQUINE; DIDANOSINE; FIALURIDINE; GENTAMICIN; HORMONE SENSITIVE LIPASE; IBUPROFEN; IRINOTECAN; METHOTREXATE; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PARACETAMOL; PERHEXILINE; PHOSPHOLIPID; REACTIVE OXYGEN METABOLITE; SALICYLIC ACID; STAVUDINE; TAMOXIFEN; TETRACYCLINE; TIANEPTINE; TRIACYLGLYCEROL; TROGLITAZONE; UNINDEXED DRUG; VALPROIC ACID; VERY LOW DENSITY LIPOPROTEIN; ZIDOVUDINE;

ADIPOSE TISSUE; ARTICLE; CELL ASSAY; CYTOSOL; DRUG INDUCED DISEASE; DRUG SCREENING; ENDOPLASMIC RETICULUM; ESTERIFICATION; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FATTY LIVER; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; KETOGENESIS; LIPID METABOLISM; LIPID PEROXIDATION; LIPID STORAGE; LIPIDOSIS; LIPOGENESIS; LIVER CELL; LIVER CIRRHOSIS; LIVER TOXICITY; MICROSCOPY; MITOCHONDRION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOGENESIS; PHOSPHOLIPID BLOOD LEVEL; PROGNOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BIOLOGICAL ASSAY; DRUG EVALUATION, PRECLINICAL; FATTY LIVER; HUMANS; LIPID METABOLISM DISORDERS; LIVER; PHARMACEUTICAL PREPARATIONS; PHOSPHOLIPIDS;

EID: 84868026974     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012802850001     Document Type: Article

References (103)

1. Kleiner, D. E.; Gaffey, M. J.; Sallie, R.; Tsokos, M.; Nichols, L.; McKenzie, R.; Straus, S. E.; Hoofnagle, J. H., Histopathologic changes associated with fialuridine hepatotoxicity. Mod. Pathol., 1997, 10 (3), 192-9.
2. Reasor, M. J.; Kacew, S., Drug-induced phospholipidosis: are there functional consequences? Exp. Biol. Med. (Maywood), 2001, 226 (9), 825-30.
3. Fromenty, B.; Pessayre, D., Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J. Hepatol., 1997, 26 Suppl 2, 43-53.
4. DiMasi, J. A.; Hansen, R. W.; Grabowski, H. G., The price of innovation: new estimates of drug development costs. J. Health Econ., 2003, 22 (2), 151-85.
5. Suter, W., Predictive value of in vitro safety studies. Curr. Opin. Chem. Biol., 2006, 10 (4), 362-6.
6. Anderson, N.; Borlak, J., Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol. Rev., 2008, 60 (3), 311-57.
7. Amacher, D. E., The mechanistic basis for the induction of hepatic steatosis by xenobiotics. Expert. Opin. Drug Metab. Toxicol., 2011, 7 (8), 949-65.
8. Cohen, J. C.; Horton, J. D.; Hobbs, H. H., Human fatty liver disease: old questions and new insights. Science, 2011, 332 (6037), 1519-23.
9. Browning, J. D.; Horton, J. D., Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest., 2004, 114 (2), 147-52.
10. Uyeda, K.; Repa, J. J., Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab., 2006, 4 (2), 107-10.
11. Horton, J. D.; Goldstein, J. L.; Brown, M. S., SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest., 2002, 109 (9), 1125-31.
12. Li, J. N.; Mahmoud, M. A.; Han, W. F.; Ripple, M.; Pizer, E. S., Sterol regulatory element-binding protein-1 participates in the regulation of fatty acid synthase expression in colorectal neoplasia. Exp. Cell Res., 2000, 261 (1), 159-65.
13. Feldstein, A. E.; Werneburg, N. W.; Canbay, A.; Guicciardi, M. E.; Bronk, S. F.; Rydzewski, R.; Burgart, L. J.; Gores, G. J., Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology, 2004, 40 (1), 185-94.
14. Foster, D. W., The role of the carnitine system in human metabolism. Ann. N Y Acad. Sci., 2004, 1033, 1-16.
15. Bonnefont, J. P.; Djouadi, F.; Prip-Buus, C.; Gobin, S.; Munnich, A.; Bastin, J., Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol. Aspects Med., 2004, 25 (5-6), 495-520.
16. Ruderman, N. B.; Saha, A. K.; Kraegen, E. W., Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity. Endocrinology, 2003, 144 (12), 5166-71.
17. Braissant, O.; Foufelle, F.; Scotto, C.; Dauca, M.; Wahli, W., Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology, 1996, 137 (1), 354-66.
18. Lefebvre, P.; Chinetti, G.; Fruchart, J. C.; Staels, B., Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J. Clin. Invest., 2006, 116 (3), 571-80.
19. Spiegelman, B. M., Transcriptional control of mitochondrial energy metabolism through the PGC1 coactivators. Novartis Found Symp., 2007, 287, 60-3; discussion 63-9.
20. Yoon, J. C.; Puigserver, P.; Chen, G.; Donovan, J.; Wu, Z.; Rhee, J.; Adelmant, G.; Stafford, J.; Kahn, C. R.; Granner, D. K.; Newgard, C. B.; Spiegelman, B. M., Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature, 2001, 413 (6852), 131-8.
21. Vega, R. B.; Huss, J. M.; Kelly, D. P., The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol. Cell Biol., 2000, 20 (5), 1868-76.
22. Hussain, M. M.; Bakillah, A., New approaches to target microsomal triglyceride transfer protein. Curr. Opin. Lipidol., 2008, 19 (6), 572-8.
23. McCarthy, T. C.; Pollak, P. T.; Hanniman, E. A.; Sinal, C. J., Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-alpha target gene activation. J. Pharmacol. Exp. Ther., 2004, 311 (3), 864-73.
24. den Boer, M.; Voshol, P. J.; Kuipers, F.; Havekes, L. M.; Romijn, J. A., Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler. Thromb. Vasc. Biol., 2004, 24 (4), 644-9.
25. Zimmerman, H. J., The adverse effects of drugs and other chemicals on the liver. In Hepatotoxicity, Lippincott Williams & Wilkins Philadelphia, 1999; p 61.
26. Begriche, K.; Massart, J.; Robin, M. A.; Borgne-Sanchez, A.; Fromenty, B., Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J. Hepatol., 2011, 54 (4), 773-94.
27. Gunel, N.; Coskun, U.; Toruner, F. B.; Sancak, B.; Yilmaz, E.; Cengiz, O.; Elbeg, S.; Uner, A.; Ozkan, S., Serum leptin levels are associated with tamoxifen-induced hepatic steatosis. Curr. Med. Res. Opin., 2003, 19 (1), 47-50.
28. Nemoto, Y.; Saibara, T.; Ogawa, Y.; Zhang, T.; Xu, N.; Ono, M.; Akisawa, N.; Iwasaki, S.; Maeda, T.; Onishi, S., Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen. Intern. Med., 2002, 41 (5), 345-50.
29. Gopaul, V. S.; Tang, W.; Farrell, K.; Abbott, F. S., Amino acid conjugates: metabolites of 2-propylpentanoic acid (valproic acid) in epileptic patients. Drug Metab. Dispos., 2003, 31 (1), 114-21.
30. Letteron, P.; Sutton, A.; Mansouri, A.; Fromenty, B.; Pessayre, D., Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology, 2003, 38 (1), 133-40.
31. Lee, M. H.; Hong, I.; Kim, M.; Lee, B. H.; Kim, J. H.; Kang, K. S.; Kim, H. L.; Yoon, B. I.; Chung, H.; Kong, G.; Lee, M. O., Gene expression profiles of murine fatty liver induced by the administration of valproic acid. Toxicol. Appl. Pharmacol., 2007, 220 (1), 45-59.
32. Labbe, G.; Pessayre, D.; Fromenty, B., Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam. Clin. Pharmacol., 2008, 22 (4), 335-53.
33. Pessayre, D.; Mansouri, A.; Berson, A.; Fromenty, B., Mitochondrial involvement in drug-induced liver injury. Handb. Exp. Pharmacol., 2010, (196), 311-65.
34. Chen, C.; Krausz, K. W.; Shah, Y. M.; Idle, J. R.; Gonzalez, F. J., Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem. Res. Toxicol., 2009, 22 (4), 699-707.
35. Silva, M. F.; Ruiter, J. P.; L, I. J.; Jakobs, C.; Duran, M.; de Almeida, I. T.; Wanders, R. J., Differential effect of valproate and its Delta2- and Delta4-unsaturated metabolites, on the beta-oxidation rate of long-chain and medium-chain fatty acids. Chem. Biol. Interact., 2001, 137 (3), 203-12.
36. Aires, C. C.; Ijlst, L.; Stet, F.; Prip-Buus, C.; de Almeida, I. T.; Duran, M.; Wanders, R. J.; Silva, M. F., Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. Biochem. Pharmacol., 2010, 79 (5), 792-9.
37. Ashrafian, H.; Horowitz, J. D.; Frenneaux, M. P., Perhexiline. Cardiovasc. Drug Rev., 2007, 25 (1), 76-97.
38. Fulgencio, J. P.; Kohl, C.; Girard, J.; Pegorier, J. P., Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes, 1996, 45 (11), 1556-62.
39. Larosche, I.; Letteron, P.; Fromenty, B.; Vadrot, N.; Abbey-Toby, A.; Feldmann, G.; Pessayre, D.; Mansouri, A., Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. J. Pharmacol. Exp. Ther., 2007, 321 (2), 526-35.
40. Deschamps, D.; DeBeco, V.; Fisch, C.; Fromenty, B.; Guillouzo, A.; Pessayre, D., Inhibition by perhexiline of oxidative phosphorylation and the beta-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology, 1994, 19 (4), 948-61.
41. Chariot, P.; Drogou, I.; de Lacroix-Szmania, I.; Eliezer-Vanerot, M. C.; Chazaud, B.; Lombes, A.; Schaeffer, A.; Zafrani, E. S., Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J. Hepatol., 1999, 30 (1), 156-60.
42. Begriche, K.; Igoudjil, A.; Pessayre, D.; Fromenty, B., Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion, 2006, 6 (1), 1-28.
43. Berson, A.; De Beco, V.; Letteron, P.; Robin, M. A.; Moreau, C.; El Kahwaji, J.; Verthier, N.; Feldmann, G.; Fromenty, B.; Pessayre, D., Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology, 1998, 114 (4), 764-74.
44. Nishino, M.; Hayakawa, K.; Nakamura, Y.; Morimoto, T.; Mukaihara, S., Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am. J. Roentgenol., 2003, 180 (1), 129-34.
45. Amacher, D. E., Strategies for the early detection of drug-induced hepatic steatosis in preclinical drug safety evaluation studies. Toxicology, 2011, 279 (1-3), 10-8.
46. Ringseis, R.; Muschick, A.; Eder, K., Dietary oxidized fat prevents ethanol-induced triacylglycerol accumulation and increases expression of PPARalpha target genes in rat liver. J. Nutr., 2007, 137 (1), 77-83.
47. Amacher, D. E.; Martin, B. A., Tetracycline-induced steatosis in primary canine hepatocyte cultures. Fundam. Appl. Toxicol., 1997, 40 (2), 256-63.
48. McMillian, M. K.; Grant, E. R.; Zhong, Z.; Parker, J. B.; Li, L.; Zivin, R. A.; Burczynski, M. E.; Johnson, M. D., Nile Red binding to HepG2 cells: an improved assay for in vitro studies of hepatosteatosis. In Vitr. Mol. Toxicol., 2001, 14 (3), 177-90.
49. Igoudjil, A.; Massart, J.; Begriche, K.; Descatoire, V.; Robin, M. A.; Fromenty, B., High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes. Toxicol. In Vitro, 2008, 22 (4), 887-98.
50. Fujimura, H.; Murakami, N.; Kurabe, M.; Toriumi, W., in vitro assay for drug-induced hepatosteatosis using rat primary hepatocytes, a fluorescent lipid analog and gene expression analysis. J. Appl. Toxicol., 2009, 29 (4), 356-63.
51. Donato, M. T.; Martinez-Romero, A.; Jimenez, N.; Negro, A.; Herrera, G.; Castell, J. V.; O'Connor, J. E.; Gomez-Lechon, M. J., Cytometric analysis for drug-induced steatosis in HepG2 cells. Chem. Biol. Interact., 2009, 181 (3), 417-23.
52. Donato, M. T.; Tolosa, L.; Jimenez, N.; Castell, J. V.; Gomez-Lechon, M. J., High-Content Imaging Technology for the Evaluation of Drug-Induced Steatosis Using a Multiparametric Cell-Based Assay. J. Biomol. Screen., 2011.
53. Shen, C.; Meng, Q.; Schmelzer, E.; Bader, A., Gel entrapment culture of rat hepatocytes for investigation of tetracycline-induced toxicity. Toxicol. Appl. Pharmacol., 2009, 238 (2), 178-87.
54. Wobser, H.; Dorn, C.; Weiss, T. S.; Amann, T.; Bollheimer, C.; Buttner, R.; Scholmerich, J.; Hellerbrand, C., Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res., 2009, 19 (8), 996-1005.
55. Ruan, X.; Shen, C.; Meng, Q., Establishment of a methodology for investigating protectants against ethanol-induced hepatotoxicity. Food Chem. Toxicol., 2010, 48 (5), 1145-51.
56. Antherieu, S.; Rogue, A.; Fromenty, B.; Guillouzo, A.; Robin, M. A., Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. Hepatology, 2011, 53 (6), 1895-905.
57. Gomez-Lechon, M. J.; Donato, M. T.; Martinez-Romero, A.; Jimenez, N.; Castell, J. V.; O'Connor, J. E., A human hepatocellular in vitro model to investigate steatosis. Chem. Biol. Interact., 2007, 165 (2), 106-16.
58. Cui, W.; Chen, S. L.; Hu, K. Q., Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. Am. J. Transl. Res., 2010, 2 (1), 95-104.
59. Janorkar, A. V.; King, K. R.; Megeed, Z.; Yarmush, M. L., Development of an in vitro cell culture model of hepatic steatosis using hepatocyte-derived reporter cells. Biotechnol. Bioeng., 2009, 102 (5), 1466-74.
60. Reasor, M. J.; Hastings, K. L.; Ulrich, R. G., Drug-induced phospholipidosis: issues and future directions. Expert Opin. Drug Saf., 2006, 5 (4), 567-83.
61. Alakoskela, J. M.; Vitovic, P.; Kinnunen, P. K., Screening for the drug-phospholipid interaction: correlation to phospholipidosis. ChemMedChem, 2009, 4 (8), 1224-51.
62. Morissette, G.; Ammoury, A.; Rusu, D.; Marguery, M. C.; Lodge, R.; Poubelle, P. E.; Marceau, F., Intracellular sequestration of amiodarone: role of vacuolar ATPase and macroautophagic transition of the resulting vacuolar cytopathology. Br. J. Pharmacol., 2009, 157 (8), 1531-40.
63. Kodavanti, U. P.; Mehendale, H. M., Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol. Rev., 1990, 42 (4), 327-54.
64. Anderson, N.; Borlak, J., Drug-induced phospholipidosis. FEBS Lett., 2006, 580 (23), 5533-40.
65. Mingeot-Leclercq, M. P.; Piret, J.; Brasseur, R.; Tulkens, P. M., Effect of acidic phospholipids on the activity of lysosomal phospholipases and on their inhibition by aminoglycoside antibiotics - I. Biochemical analysis. Biochem. Pharmacol., 1990, 40 (3), 489-97.
66. Piret, J.; Schanck, A.; Delfosse, S.; Van Bambeke, F.; Kishore, B. K.; Tulkens, P. M.; Mingeot-Leclercq, M. P., Modulation of the in vitro activity of lysosomal phospholipase A1 by membrane lipids. Chem. Phys. Lipids, 2005, 133 (1), 1-15.
67. Sawada, H.; Takami, K.; Asahi, S., A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol. Sci., 2005, 83 (2), 282-92.
68. Song, M.; Kim, Y. J.; Ryu, J. C., Phospholipidosis induced by PPARgamma signaling in human bronchial epithelial (BEAS-2B) cells exposed to amiodarone. Toxicol. Sci., 2011, 120 (1), 98-108.
69. Lowe, R.; Mussa, H. Y.; Nigsch, F.; Glen, R. C.; Mitchell, J. B., Predicting the mechanism of phospholipidosis. J. Cheminform., 2012, 4 (1), 2.
70. Ikeda, K.; Hirayama, M.; Hirota, Y.; Asa, E.; Seki, J.; Tanaka, Y., Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptor-mediated targeting of lysosomal enzymes. Biochem. Biophys. Res. Commun., 2008, 377 (1), 268-74.
71. Berridge, B. R.; Chatman, L. A.; Odin, M.; Schultze, A. E.; Losco, P. E.; Meehan, J. T.; Peters, T.; Vonderfecht, S. L., Phospholipidosis in nonclinical toxicity studies. Toxicol. Pathol., 2007, 35 (2), 325.
72. Yamamoto, A.; Adachi, S.; Ishikawa, K.; Yokomura, T.; Kitani, T., Studies on drug-induced lipidosis. 3. Lipid composition of the liver and some other tissues in clinical cases of "Niemann-Pick-like syndrome" induced by 4,4'-diethylaminoethoxyhexestrol. J. Biochem., 1971, 70 (5), 775-84.
73. Raja, K.; Thung, S. N.; Fiel, M. I.; Chang, C., Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use. Semin. Liver Dis., 2009, 29 (4), 423-8.
74. The regulatory challenges of drug-induced phospholipidosis. 2010. Available at: http://www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/drugs/advisorycommitteeforpharma- ceuticalscienceandclinicalpharmacology/ucm210798.pdf.
75. Nonoyama, T.; Fukuda, R., Drug-induced phospholipidosis. Pathological aspects and its prediction. J. Toxicol. Pathol., 2008, 21, 9-24.
76. Drenckhahn, D.; Kleine, L.; Lullmann-Rauch, R., Lysosomal alterations in cultured macrophages exposed to anorexigenic and psychotropic drugs. Lab. Invest., 1976, 35 (2), 116-23.
77. Chatman, L. A.; Morton, D.; Johnson, T. O.; Anway, S. D., A strategy for risk management of drug-induced phospholipidosis. Toxicol. Pathol., 2009, 37 (7), 997-1005.
78. Hasegawa, M.; Takenaka, S.; Kuwamura, M.; Yamate, J.; Tsuyama, S., Urinary metabolic fingerprinting for amiodarone-induced phospholipidosis in rats using FT-ICR MS. Exp. Toxicol. Pathol., 2007, 59 (2), 115-20.
79. Baronas, E. T.; Lee, J. W.; Alden, C.; Hsieh, F. Y., Biomarkers to monitor drug-induced phospholipidosis. Toxicol. Appl. Pharmacol., 2007, 218 (1), 72-8.
80. Clarke, C. J.; Haselden, J. N., Metabolic profiling as a tool for understanding mechanisms of toxicity. Toxicol. Pathol., 2008, 36 (1), 140-7.
81. Hirode, M.; Ono, A.; Miyagishima, T.; Nagao, T.; Ohno, Y.; Urushidani, T., Gene expression profiling in rat liver treated with compounds inducing phospholipidosis. Toxicol. Appl. Pharmacol., 2008, 229 (3), 290-9.
82. Tengstrand, E. A.; Miwa, G. T.; Hsieh, F. Y., Bis(monoacylglycerol) phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities. Expert Opin. Drug Metab. Toxicol., 2010, 6 (5), 555-70.
83. Ploemen, J. P.; Kelder, J.; Hafmans, T.; van de Sandt, H.; van Burgsteden, J. A.; Saleminki, P. J.; van Esch, E., Use of physico-chemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines. Exp. Toxicol. Pathol., 2004, 55 (5), 347-55.
84. Tomizawa, K.; Sugano, K.; Yamada, H.; Horii, I., Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential. J. Toxicol. Sci., 2006, 31 (4), 315-24.
85. Pelletier, D. J.; Gehlhaar, D.; Tilloy-Ellul, A.; Johnson, T. O.; Greene, N., Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential. J. Chem. Inf. Model., 2007, 47 (3), 1196-205.
86. Vitovic, P.; Alakoskela, J. M.; Kinnunen, P. K., Assessment of drug-lipid complex formation by a high-throughput Langmuir-balance and correlation to phospholipidosis. J. Med. Chem., 2008, 51 (6), 1842-8.
87. Zhou, L.; Geraci, G.; Hess, S.; Yang, L.; Wang, J.; Argikar, U., Predicting phospholipidosis: a fluorescence noncell based in vitro assay for the determination of drug-phospholipid complex formation in early drug discovery. Anal. Chem., 2011, 83 (18), 6980-7.
88. Cramer, C. T.; Ulrich, R. G., Cytotoxicity and lamellar body induction potential of a racemic benzamide antiarrhythmic compound and enantiomers in cultured rat hepatocytes. Toxicol. In Vitro, 1994, 8 (5), 1083-90.
89. Gum, R. J.; Hickman, D.; Fagerland, J. A.; Heindel, M. A.; Gagne, G. D.; Schmidt, J. M.; Michaelides, M. R.; Davidsen, S. K.; Ulrich, R. G., Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes(1). Biochem. Pharmacol., 2001, 62 (12), 1661-73.
90. Sawada, H.; Taniguchi, K.; Takami, K., Improved toxicogenomic screening for drug-induced phospholipidosis using a multiplexed quantitative gene expression ArrayPlate assay. Toxicol. In Vitro, 2006, 20 (8), 1506-13.
91. Atienzar, F.; Gerets, H.; Dufrane, S.; Tilmant, K.; Cornet, M.; Dhalluin, S.; Ruty, B.; Rose, G.; Canning, M., Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol. Sci., 2007, 96 (1), 101-14.
92. Nioi, P.; Perry, B. K.; Wang, E. J.; Gu, Y. Z.; Snyder, R. D., In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol. Sci., 2007, 99 (1), 162-73.
93. Kasahara, T.; Tomita, K.; Murano, H.; Harada, T.; Tsubakimoto, K.; Ogihara, T.; Ohnishi, S.; Kakinuma, C., Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential. Toxicol. Sci., 2006, 90 (1), 133-41.
94. Bhandari, N.; Figueroa, D. J.; Lawrence, J. W.; Gerhold, D. L., Phospholipidosis assay in HepG2 cells and rat or rhesus hepatocytes using phospholipid probe NBD-PE. Assay Drug Dev. Technol., 2008, 6 (3), 407-19.
95. Miyamoto, S.; Matsumoto, A.; Mori, I.; Horinouchi, A., Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats. Toxicol. Mech. Methods, 2009, 19 (8), 477-85.
96. Casartelli, A.; Bonato, M.; Cristofori, P.; Crivellente, F.; Dal Negro, G.; Masotto, I.; Mutinelli, C.; Valko, K.; Bonfante, V., A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development. Cell Biol. Toxicol., 2003, 19 (3), 161-76.
97. Morelli, J. K.; Buehrle, M.; Pognan, F.; Barone, L. R.; Fieles, W.; Ciaccio, P. J., Validation of an in vitro screen for phospholipidosis using a high-content biology platform. Cell Biol. Toxicol., 2006, 22 (1), 15-27.
98. Natalie, M.; Margino, S.; Erik, H.; Annelieke, P.; Geert, V.; Philippe, V., A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase. Toxicol. In Vitro, 2009, 23 (2), 217-26.
99. van de Water, F. M.; Havinga, J.; Ravesloot, W. T.; Horbach, G. J.; Schoonen, W. G., High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis. Toxicol. In Vitro, 2011, 25 (8), 1870-82.
100. LeCureux, L.; Cheng, C. S.; Herbst, J.; Reilly, T. P.; Lehman-McKeeman, L.; Otieno, M., Evaluation and validation of multiple cell lines and primary mouse macrophages to predict phospholipidosis potential. Toxicol. In Vitro, 2011, 25 (8), 1934-43.
101. Tilmant, K.; Gerets, H. H.; Dhalluin, S.; Hanon, E.; Depelchin, O.; Cossu-Leguille, C.; Vasseur, P.; Atienzar, F. A., Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis. Toxicol. In Vitro, 2011, 25 (7), 1414-24.
102. Schurdak, M. E.; Vernetti, L. A.; Abel, S. J.; Thiffault, C., Adaptation of an in vitro phospholipidosis assay to an automated image analysis system. Toxicol. Mech. Methods, 2007, 17 (2), 77-86.
103. Kola, I.; Landis, J., Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov., 2004, 3(8), 711-715.